Examples of 'ofatumumab' in a sentence
Meaning of "ofatumumab"
ofatumumab (adjective): Referring to a specific type of human monoclonal antibody used in the treatment of certain medical conditions, particularly autoimmune diseases
Show more definitions
- A human monoclonal antibody targeting CD20, under investigation for the treatment of chronic lymphocytic leukemia and other diseases.
How to use "ofatumumab" in a sentence
Basic
Advanced
ofatumumab
Ofatumumab should be a colourless to pale yellow solution.
There are no data on the effects of ofatumumab on human fertility.
Intravenous ofatumumab has been associated with infusion reactions.
Idelalisib in combination with ofatumumab.
The excretion of ofatumumab in milk has not been studied in animals.
The active substance is ofatumumab.
Do not shake the ofatumumab vial for this inspection.
Ofatumumab is currently used as a treatment for chronic lymphocytic leukaemia.
There are no data from the use of ofatumumab in pregnant women.
Ofatumumab is given through a needle placed in one of your veins.
Do not shake the botulinum of ofatumumab for this check.
There is a potential for immunogenicity with therapeutic proteins such as ofatumumab.
The safe use of ofatumumab in humans during lactation has not been established.
Arzerra is a cancer medicine that contains the active substance ofatumumab.
Patients randomised to ofatumumab were censored when starting IMBRUVICA if applicable.
See also
Live attenuated or inactivated vaccine efficacy may be impaired with ofatumumab.
Zydelig with ofatumumab was more effective than ofatumumab alone in the treatment of CLL.
No detrimental effects on such activities are predicted from the pharmacology of ofatumumab.
Peripheral B cells counts decreased after the first ofatumumab infusion in patients with haematologic malignancies.
This has resulted in liver failure or death in some people using ofatumumab.
Ofatumumab can cause hepatitis B to come back or get worse.
It is contraindicated in individuals that have hypersensitivity to ofatumumab or any of its excipients.
Ofatumumab is administered by intravenous infusion ; therefore, absorption is not applicable.
The risks and benefits of vaccinating patients during therapy with ofatumumab should be considered.
Intravenous ofatumumab has been associated with infusion-related reactions.
Direct killing is shown against different concentrations of Ofatumumab.
In some patients, ofatumumab is given with another medicine called chlorambucil.
These cells were subsequently stained with either Rituximab or Ofatumumab.
Ofatumumab had non-linear pharmacokinetics related to its decreasing clearance over time.
Bendamustine and Ofatumumab.
As ofatumumab is a monoclonal antibody, genotoxicity and carcinogenicity studies have not been conducted with ofatumumab.
The preparation contains the substance, ofatumumab.
A test dose of ofatumumab with appropriate pre-medication should be considered in patients with rituximab intolerance.
Therefore, the concomitant use of these agents with ofatumumab should be avoided.
Ofatumumab is a fully human monoclonal antibody which is sold as ARZERRA ®.
Breastfeeding should be discontinued during treatment with ofatumumab and for 12 months following treatment.
Ofatumumab is a human monoclonal antibody produced in a recombinant murine cell line NS0.
Fifty-seven patients randomised to ofatumumab crossed over following progression to receive IMBRUVICA.
Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.
Peripheral B-cell counts decreased after the first ofatumumab infusion in patients with haematological malignancies.
Novartis will be responsible for the worldwide development, regulatory and commercialisation activities for Ofatumumab.
Hypersensitivity to ofatumumab or to any of the excipients listed in section 6.1.
The present work provides a molecular rationale for CD20 modulation induced by rituximab and ofatumumab.
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
What Arzerra contains - The active substance is ofatumumab.
After the diafiltration into the platform buffer, ofatumumab was concentrated to a maximum concentration of 179 mg / mL.
T-cells are remarkably sensitive to Ofatumumab.
Table 5 Ofatumumab pharmacokinetic parameters ( geometric mean ).
One ml of concentrate contains 20 mg of ofatumumab.
When ofatumumab attaches to CD20, it causes the cell to die.
